Study Investigates Asthma Drug’s Impact on Parkinson’s Disease

Understanding Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurological disorder marked by tremors, motor dysfunction, and muscle discomfort. This condition arises from the degeneration and eventual death of brain cells within regions that govern movement and muscle coordination. A critical factor in this degeneration is the accumulation of misfolded α-synuclein protein in these neurons.

Research Focus on α-Synuclein

In the quest for effective treatments for PD, researchers are exploring drugs that target α-synuclein, primarily by preventing its aggregation. Recent investigations are shifting towards reducing the production of α-synuclein itself.

Recent Findings on Salbutamol

A recent study published in the journal Science explored the effects of various substances on the production of α-synuclein in brain cells. Researchers tested over 1,100 candidate drugs, vitamins, and supplements, identifying salbutamol, an asthma medication, as a significant reducer of α-synuclein gene (SNCA) activity, subsequently lowering α-synuclein protein levels.

Salbutamol activates the β2-adrenoreceptor (β2AR), which typically opens airways but also decreases SNCA activity by enhancing histone acetylation. This process involves the binding of histone proteins to DNA, which can restrict access to the gene and its products. Acetylation, the addition of acetyl groups to histones, generally tightens this binding, making the gene less accessible.

Impact of Salbutamol on Parkinson’s Disease Incidence

To evaluate the relationship between salbutamol use and Parkinson’s disease incidence, researchers analyzed health records of over 4 million Norwegian patients over an 11-year span. The findings indicated that salbutamol users experienced a 34% reduction in the likelihood of developing PD. Notably, individuals who used high doses of salbutamol from 2004 to 2007 had a 50% lower risk of PD from 2008 to 2014 compared to those who used minimal doses. Conversely, blocking β2AR function was linked to an elevated risk of PD.

Despite these findings, the overall incidence of PD in the study population was low, with approximately 0.1% among non-users of salbutamol and less than 0.04% among users. Additionally, β2AR activation was shown to reduce PD incidence in both mice and human brain cell cultures, highlighting the potential of salbutamol and similar drugs in treating and preventing PD.

Future Directions and Clinical Implications

These groundbreaking findings suggest that salbutamol may offer significant benefits in treating Parkinson’s disease. More broadly, activating β2AR could represent a promising therapeutic approach for PD. Given that salbutamol does not easily penetrate the blood-brain barrier, research into β2AR activators that can cross this barrier may provide further insights.

Moreover, conducting clinical studies in more diverse populations with higher rates of Parkinson’s disease could enhance our understanding of other contributing factors and the role of β2AR activation. Clinical trials are currently in progress.

Conclusion

The potential of salbutamol as a treatment for Parkinson’s disease opens new avenues for research and therapeutic strategies aimed at reducing the risk and impact of this debilitating condition.

Written by Raishard Haynes, MBS

References:
http://www.sciencemag.org/news/2017/08/asthma-drug-may-thwart-parkinson-s-disease
http://science.sciencemag.org/content/357/6354/891